PulmoSIM Therapeutics (PulmoSIM), the pharmaceutical subsidiary of VeriSIM Life, Inc., is pleased to announce today that it has entered into a strategic partnership with the investigators from National Jewish Health and Brown University for the clinical development of PT001, a drug that targets multiple responsible pathways in PAH to provide curative treatment. The Food and Drug Administration (FDA) recently granted orphan drug designation for PT001 for the treatment of PAH.